Differing HOAs in cataract patients

Article

Different types of early lenticular opacities in cataract patients induce different wavefront aberration profiles, according to a study published in the August issue of the Journal of Cataract and Refractive Surgery.

Different types of early lenticular opacities in cataract patients induce different wavefront aberration profiles, according to a study published in the August issue of the Journal of Cataract and Refractive Surgery.

Karolinne Maia Rocha and colleagues from the Federal University of Sao Paulo, Brazil, looked at 105 eyes of 65 patients with bilateral cataract, classified according to the Lens Opacities Classification System III (LOCS III). All eyes underwent a complete ophthalmic examination, including corneal topography and wavefront analysis. Higher order aberrations were compared between the nuclear, cortical and posterior subcapsular groups for statistical significance.

The researchers found that 28 eyes (23.3%) had predominantly nuclear opacification and 13 (10.83%) had mainly cortical opacification. Sixty-four eyes had a mixed pattern of LOCS III classification, which hindered the establishment of a correlation between the aberrometry and cataract type.

In eyes with nuclear opacification, the mean spherical aberration with a 6 mm pupil was 0.45±0.17 µm and the mean coma was 0.29±0.13 µm. In eyes with predominantly cortical cataract, mean spherical aberration was 0.12±0.10 µm and the mean coma was 0.49±0.23 µm. The cortical cataract group had significantly higher coma than any other group (p<0.001) and the nuclear cataract group had significantly higher spherical aberrations than the other groups (p<0.001).

It was concluded that different types of early lenticular opacities induce different wavefront aberration profiles.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.